EANS-Adhoc: Marinomed Biotech AG announces top line results of the Phase III study for Budesolv

--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development
23.04.2019

Vienna - Marinomed Biotech AG, a globally active biopharmaceutical company with
headquarters in Vienna, has announced the successful completion of the pivotal
Phase III study for Budesolv. The top line results are now available and show
that Budesolv achieves at least the same effect as the product which is
currently on the market, with a significantly lower dose. The planned primary
endpoint of the study for the first product of the innovative Marinosolv®
technology platform has thus been achieved. The approval process can be
continued as scheduled.

As announced, the complete Phase III study with detailed results is expected and
will be published by the end of the second quarter of 2019 at the latest.

Marinosolv® and the flagship product Budesolv
Marinomed has succeeded in increasing the bioavailability of hardly soluble
compounds to treat sensitive tissues such as nose and eyes via the Marinosolv®
technology platform. The platform's flagship product is Budesolv, a nasal spray
for the treatment of allergic rhinitis.

About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna
and has been listed in the Prime Market of the Vienna Stock Exchange since
February 1, 2019. The company focuses on the development of innovative products
based on patent-protected technology platforms in the field of respiratory and
ophthalmological diseases. The Marinosolv® technology platform increases the
efficacy of hardly soluble compounds for the treatment of sensitive tissues such
as the eyes and nose. The Carragelose® platform comprises innovative patent-
protected products targeting viral infections of the respiratory tract.
Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold
via international partners in over 30 countries worldwide. Further information
is available at: www.marinomed.com [http://www.marinomed.com/].

Further inquiry note:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Wien, Austria
T +43 (0)1 250 77 446
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Wien, Austria
T +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Original-Content von: Marinomed Biotech AG, übermittelt durch news aktuell